Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

[Molecular targeting therapy of dyslipidemia].

Hara M, Kinoshita M.

Nihon Rinsho. 2012 Nov;70 Suppl 8:618-22. Japanese. No abstract available.

PMID:
23513913
2.

Novel strategies for managing dyslipidemia: treatment beyond statins.

Ling H, Burns TL, Hilleman DE.

Postgrad Med. 2012 Nov;124(6):43-54. doi: 10.3810/pgm.2012.11.2612. Review.

PMID:
23322138
3.

Ongoing challenges for pharmacotherapy for dyslipidemia.

Pisaniello AD, Scherer DJ, Kataoka Y, Nicholls SJ.

Expert Opin Pharmacother. 2015 Feb;16(3):347-56. doi: 10.1517/14656566.2014.986094. Epub 2014 Dec 5. Review.

PMID:
25476544
4.

Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapies.

Kohli P, Giugliano RP.

J Cardiovasc Pharmacol Ther. 2013 May;18(3):199-210. doi: 10.1177/1074248413480270. Review.

PMID:
23580658
5.

Novel cholesteryl ester transfer protein inhibitors: promising therapy for dyslipidemia?

Devaraj S, Jialal I.

Metab Syndr Relat Disord. 2011 Jun;9(3):163-5. doi: 10.1089/met.2011.1500. Epub 2011 May 10. No abstract available.

PMID:
21557663
6.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Review.

PMID:
23932550
7.

The effects of medications used for the management of dyslipidemia on postprandial lipemia.

Tentolouris N, Eleftheriadou I, Katsilambros N.

Curr Med Chem. 2009;16(2):203-17. Review.

PMID:
19149572
8.

The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.

Hajhosseiny R, Sabir I, Khavandi K, Wierzbicki AS.

Clin Pharmacol Ther. 2014 Jul;96(1):64-73. doi: 10.1038/clpt.2014.76. Epub 2014 Apr 3. Review.

PMID:
24699033
9.

[Clinical significance of and treatment options for increased lipoprotein(a)].

Zsíros N, Paragh G, Harangi M.

Orv Hetil. 2014 Apr 20;155(16):607-14. doi: 10.1556/OH.2014.29877. Review. Hungarian.

PMID:
24733102
10.

Potential peptides in atherosclerosis therapy.

Marleau S, Mellal K, Huynh DN, Ong H.

Front Horm Res. 2014;43:93-106. doi: 10.1159/000360568. Epub 2014 Jun 10. Review.

PMID:
24943301
11.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
12.

Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.

Li C, Zhang W, Zhou F, Chen C, Zhou L, Li Y, Liu L, Pei F, Luo H, Hu Z, Cai J, Zeng C.

PLoS One. 2013 Oct 28;8(10):e77049. doi: 10.1371/journal.pone.0077049. eCollection 2013. Review.

13.

Anacetrapib: a new weapon against dyslipidemia.

Aperis G, Paliouras C, Tsampikaki E, Papakonstantinou N, Alivanis P.

Curr Clin Pharmacol. 2011 Nov;6(4):227-35. Review.

PMID:
22082322
14.

High-density lipoprotein cholesterol as the Holy Grail.

Cannon CP.

JAMA. 2011 Nov 16;306(19):2153-5. doi: 10.1001/jama.2011.1687. No abstract available.

PMID:
22089726
15.

Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?

Page MM, Hooper AJ, Burnett JR.

Expert Opin Pharmacother. 2016;17(2):275-81. doi: 10.1517/14656566.2016.1129402. Epub 2015 Dec 28. Review.

PMID:
26642232
16.

The treatment of dyslipidemia--what's left in the pipeline?

Rau O, Zettl H, Popescu L, Steinhilber D, Schubert-Zsilavecz M.

ChemMedChem. 2008 Feb;3(2):206-21. Review.

PMID:
17963209
17.

Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia.

Davidson MH.

EBioMedicine. 2015 Mar 9;2(4):284. doi: 10.1016/j.ebiom.2015.03.004. eCollection 2015 Apr. No abstract available.

18.

The evolving role of CETP inhibition: beyond HDL cholesterol.

Ray KK, Vallejo-Vaz AJ.

Lancet. 2015 Aug 1;386(9992):412-4. doi: 10.1016/S0140-6736(15)60608-0. Epub 2015 Jun 2. No abstract available.

PMID:
26047976
19.

[Current status of development of anti-dyslipidemic drugs].

Yokode M.

Nihon Rinsho. 2007 Jul 28;65 Suppl 7:494-8. Review. Japanese. No abstract available.

PMID:
17824077
20.

Familial hypercholesterolemia: present and future management.

Sjouke B, Kusters DM, Kastelein JJ, Hovingh GK.

Curr Cardiol Rep. 2011 Dec;13(6):527-36. doi: 10.1007/s11886-011-0219-9. Review.

Supplemental Content

Support Center